Abstract
The multi-state and concertation procedures have generally been successful, but there is room for improvement. Pharmaceutical companies, regulatory agencies, and the European Commission must work together to truly achieve a single European pharmaceutical market. These remarks discuss actions which could be introduced to facilitate the transition from the old regulatory system to the new.
Get full access to this article
View all access options for this article.